ClinicalTrials.gg
CompletedNCT05448001Updated Aug 26, 2024

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

A Phase 3 interventional study of JP-1366 20mg and Lansoprazole 30mg in Gastric Ulcer, sponsored by Onconic Therapeutics Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Onconic Therapeutics Inc. (part of Jeil Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
329
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Stomach Ulcer with a site in Korea, Republic of — 2 open to participants now, 2 under way, 1 of them phase 3. Stomach Ulcer · Korea, Republic of.

Enrollment
5th of 17
329 · median 199
Started
2022
the only one that year
Phase 3
7 of 20
1 open now
Registered
15th of 20
by date

Among the 20 studies in Stomach Ulcer with a site in Korea, Republic of, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 3, and was the 15th registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

2 of the 20 studies in Stomach Ulcer with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Stomach Ulcer with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Multi-center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients with Gastric Ulcer

03

Conditions studied

  • Gastric Ulcer

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Inclusion Criteria: Subjects who meet all of the following criteria can participate in this study:

    1. Male or female, ≥ 19 years of age at the time of obtaining consent
    2. Confirmation via upper gastrointestinal endoscopy within 14 days from Visit 2 for the following:

      º One or more GUs with the largest ulcer ≥ 3 mm to ≤ 30 mm

      º Largest ulcer classified as A1 or A2 based on Sakita-Miwa classification

    3. Subjects who fully understand this study and voluntarily signed the form
  • Exclusion Criteria: Subjects who meet any of the following criteria cannot participate in this trial:

[Medical History]

  1. Subjects who have undergone gastric acid secretion suppression surgery, gastric surgery (e.g., gastrectomy and gastromucosectomy), resection of entire small bowel (excluding simple ulcer closure and endoscopic benign tumor resection) or esophageal surgery
  2. Subjects with history of Zollinger-Ellison syndrome or gastric hypersecretion
  3. Subjects with (present or past) to any substance in the IP, drugs in the same class as them (potassium-competitive acid blocker [P-CAB] and proton pump ingibitor[PPI]), or benzimidazole
  4. Subjects with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  5. Subjects with malignant gastrointestinal cancer regardless of the period, Subjects with a history of within 5 years from Visit 1 (however, subjects with basal cell carcinoma or squamous cell carcinoma who require steady long-term follow-up only without therapeutic dosing/procedure/surgery, etc. can participate in this trial)
  6. Subjects with a history of drug or alcohol abuse within 1 year from Visit 1.
  7. Subjects who have had or are scheduled to have major surgery that may affect gastric acid secretion within 30 days from Visit 1

    [Comorbidity]

  8. Subjects with gastrointestinal bleeding, esophageal stricture, ulcer-induced stenosis, pyloric stenosis, gastroesophageal varices, Barrett's esophagus (> 3 cm), esophageal dysplasia, duodenal ulcer, glandular ulcer, ulcer, perforation ulcer, or surgery-induced ulcer at Visit 1
  9. Subjects with signal symptoms (dysphagia, severe dysphagia, bleeding, weight loss, anemia, and bloody stools) that suggest malignant tumors of gastrointestinal tract at Visit 1 (except a tumor confirmed negative in endoscopy, etc.)
  10. Subjects with pancreatitis, inflammatory bowel Disease (Crohn's disease, ulcerative colitis, or Behcet's enteritis) at Visit 1
  11. Subjects with known acquired immune deficiency syndrome (AIDS) or hepatitis (including surface (HBs) antigen positive, virus (HCV) antibody positive, or hepatitis virus carrier) (except subjects that are HCV-RNA negative)
  12. Subject with mental illness
  13. Thrombotic patients (cerebral thrombosis, myocardial infarction, thrombophlebitis, etc.)
  14. Subjects who confirmed malignant tumors by upper gastrointestinal endoscopy during the Screening (Visit 1). If a is required. Subject who may have an impact on the lesion evaluated in this clinical trial needs to be excluded, and the biopsy should not be delayed for registration in this clinical trial.

    [Drug Dosing/Treatment History]

  15. Subjects with a history of taking any of the following drugs or those required to take them until the end of treatment (EOT): For participation in this trial, stable drugs must not be discontinued.:

    \<Drugs prohibited from within 2 weeks of Visit 1 to EOT>

    º All acid blockers other than the IPs: H2 receptor antagonists, proton pump inhibitors (PPIs) and potassium-competitive gastric acid blockers

    º Gastromucosal protection agents: Prostaglandins (however, local administration is allowed) and mucosal blood flow stimulants Antacids

    º Gastrointestinal motility stimulants

    º Anticholinergics (however, local administration is allowed)

    º Cholinergic agents (however, local administration is allowed)

    º Glucocorticosteroids (however, local administration is allowed)

    º Gastrin receptor antagonist, other drugs for the treatment of peptic ulcer

    \<Drugs prohibited from Visit 1 to EOT>

    º Rilpivirine, atazanavir, and nelfinavir

    º Antipsychotics, antidepressants, and antianxiety drugs

    \<1 week prior to the date of upper gastrointestinal endoscopy(EGD)>

    º Non-steroidal anti-inflammatory drugs (NSAIDs)

    º Antithrombotic agents: Anticoagulants or antiplatelet drugs

    However, among the above drugs, drugs administered as a pre-treatment for upper gastrointestinal endoscopy or for an urea breath test are allowed

    : midazolam, propofol, simethicone, hyoscine butylbromide, cimetropium bromide, magmil, pethidine, gasocol, urea, etc.

  16. Subjects who have participated in another clinical trial within 4 weeks from Visit 1 and have been administered with or used an IP or medical device at least once
  17. Subjects who have received H.pylori eradication treatment within 4 weeksfrom the date of upper gastrointestinal endoscopy.
  18. Subjects who have clinically significant abnormal

    [Laboratory Tests]

  19. Blood test results meet the criteria below at Visit 1:

    º , AST, ALP, GGT, Total > 2.0 x

    º \< 60 mL/min/1.73 m2

    [Other]

  20. Subjects who cannot undergo upper gastrointestinal endoscopy
  21. Pregnant or breast-feeding women
  22. Women and men of who are unwilling to use an appropriate medically acceptable method of during the entire study period (Visit 1 through the end of study visit)
  23. Subjects who are judged unsuitable for participation in this trial by the investigators for other reasons
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
329 participants (actual)

Study arms

  • Experimental
    Study Group

    Drug: JP-1366 20mg

  • Active comparator
    Control Group

    Drug: Lansoprazole 30mg

Interventions

  • JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal

  • JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal

06

What researchers measure

Primary outcomes

  1. Cumulative complete healing rate for ulcer confirmed by upper gastrointestinal endoscopy by Week 8

    Time frame: Week 8

Secondary outcomes

  1. Complete healing rate for ulcers confirmed by upper gastrointestinal endoscopy at Week 4

    Time frame: Week 4

  2. Complete healing rate for ulcer confirmed by upper gastrointestinal endoscopy at Week 4 by Helicobacter pylori infection status

    Time frame: Week 4

  3. Cumulative complete healing rate for ulcer confirmed by upper gastrointestinal endoscopy according to Helicobacter pylori infection status by Week 8

    Time frame: Week 8

  4. Changes of Gastrointestinal symptoms per NDI-K at week 4 and 8

    The frequency and severity of 15 gastointestinal symptoms were scored on a scale from 0 to 4 using a score sheet.

    Time frame: Week 4 and 8

  5. Changes in quality of life (EQ-5D-5L) at Weeks 4 and 8

    Time frame: Week 4 and 8

  6. Changes and the proportion of changes of the ulcer size(s) at week 4 and week 8

    Subjects will also rate their health status on the visual analogue scale (VAS) between 0 (the worst state) and 100 (the best state) to get the score for their overall health.

    Time frame: Week 4 and 8

  7. Change of the number of ulcer(s) at week 4 and week 8

    Time frame: Week 4 and 8

Other outcomes

  1. Exploratory Endpoints

    Blood Gastrin Test

    Time frame: 2weeks after the end of treatment

07

Study locations

1 site
  • Korea University Kuro Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Jul 2024, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jul 7, 2022
StartActual
Sep 19, 2022
Primary completionActual
Jul 10, 2024
CompletionActual
Jul 19, 2024
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05448001
Responsible party
Sponsor
First posted
Jul 7, 2022
Start date
Sep 19, 2022
Primary completion
Jul 10, 2024
Completion
Jul 19, 2024
Last update
Aug 26, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zastaprazan

Start the discussion